IGC Pharma (IGC) Non-Current Debt (2010 - 2026)
IGC Pharma's (IGC) quarterly Non-Current Debt came in at $917000.0 in Q1 2026, up 584.33% year-over-year from $134000.0 in Q1 2025, and up 194.86% quarter-over-quarter from $311000.0 in Q4 2025.
Powered by 
Analysis
IGC Pharma (IGC) Non-Current Debt (2010 - 2026) Analysis & Trends
IGC Pharma (IGC) has reported Non-Current Debt for 15 consecutive years, with $917000.0 the latest figure, recorded in Q1 2026.
- On a quarterly basis, Non-Current Debt rose 584.33% year-over-year to $917000.0 in Q1 2026; TTM through Mar 2026 was $917000.0, a 584.33% increase from a year earlier, with the FY2026 full-year figure at $917000.0, up 584.33% from the prior year.
- Non-Current Debt was $917000.0 for Q1 2026 at IGC Pharma, up from $311000.0 in the prior quarter.
- Over five years, Non-Current Debt peaked at $917000.0 in Q1 2026 and troughed at $132000.0 in Q3 2025.
- A 5-year average of $193941.2 and a median of $139000.0 in 2023 frame the typical range for Non-Current Debt.
- Across the five-year window, Non-Current Debt sank 47.83% in 2022 and surged 584.33% in 2026, its largest moves.
- Over 5 years, Non-Current Debt stood at $141000.0 in 2022, then dropped by 2.13% to $138000.0 in 2023, then decreased by 2.9% to $134000.0 in 2024, then jumped by 132.09% to $311000.0 in 2025, then jumped by 194.86% to $917000.0 in 2026.
- The last three Non-Current Debt figures came in at $917000.0 (Q1 2026), $311000.0 (Q4 2025), and $132000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 57.30 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 26.25 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.99 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 591.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 7.29 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | IGC Pharma | 27.77 Mn | 27.51 Mn | - | 917,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 917,000.00 |
| Dec 31, 2025 | 311,000.00 |
| Sep 30, 2025 | 132,000.00 |
| Jun 30, 2025 | 133,000.00 |
| Mar 31, 2025 | 134,000.00 |
| Dec 31, 2024 | 134,000.00 |
| Sep 30, 2024 | 135,000.00 |
| Jun 30, 2024 | 136,000.00 |
| Mar 31, 2024 | 137,000.00 |
| Dec 31, 2023 | 138,000.00 |
| Sep 30, 2023 | 139,000.00 |
| Jun 30, 2023 | 140,000.00 |
| Mar 31, 2023 | 141,000.00 |
| Dec 31, 2022 | 141,000.00 |
| Sep 30, 2022 | 142,000.00 |
| Jun 30, 2022 | 143,000.00 |
| Mar 31, 2022 | 144,000.00 |
| Dec 31, 2021 | 145,000.00 |
| Sep 30, 2021 | 146,000.00 |
| Jun 30, 2021 | 147,000.00 |